Skip to content

Brain Health Nexus

Speakers

Sandro Galea, MD, MPH, DrPH
Sandro Galea, MD, MPH, DrPH

Dean & Robert A. Knox Professor
Boston University School of Public Health

Holly Garriock, PhD
Holly Garriock, PhD

Chief Cohort Development Officer,
All of Us Research Program

National Institutes of Health

Magali Haas, MD, PhD
Magali Haas, MD, PhD

CEO & President
Cohen Veterans Bioscience

bhn-anthony-hassan-alt
Anthony M. Hassan, EdD, LCSW

President & CEO
Cohen Veterans Network

Brad Herbert, MBA
Brad Herbert, MBA

CEO
Healthy Brains Global Initiative

Peter Hoehn
Peter Hoehn

Head, Commercial Strategy 
Johnson & Johnson Science for Minds

Lee Lancashire, PhD
Lee Lancashire, PhD

CIO
Cohen Veterans Bioscience

Pierre Meulien, PhD
Pierre Meulien, PhD

Executive Director
Innovative Medicines Initiative

bhn-speaker-ekemini-riley
Ekemini Riley, PhD

Managing Director
Brin Family Foundation

Lita Sands, MBA
Lita Sands, MBA

Head of Global Life Sciences Business Development
Amazon Web Services

Chris Van Hoof, PhD
Chris Van Hoof, PhD

Vice President, R&D
imec

Share Your Thoughts - Take the Nexus Survey

We need your voice to help shape the future of this effort and make effective change. 

We invite you to join our network of advocates and lend your expertise to this coordinated action in response to this global public health crisis.

Please watch this webinar to learn more about our goals and the scope of this effort, and most important, please complete the survey.

We want your perspective and expertise on current barriers, prioritized gaps, and a possible course of action. The survey will feed into a white paper that will build toward a roadmap designed for collaborative engagement.

Sandro Galea, MD, MPH, DrPH

Dean & Robert A. Knox Professor
Boston University School of Public Health

Sandro Galea, a physician, epidemiologist, and author, is dean and Robert A. Knox Professor at Boston University School of Public Health. He previously held academic and leadership positions at Columbia University, the University of Michigan, and the New York Academy of Medicine. He has published extensively in the peer-reviewed literature, and is a regular contributor to a range of public media, about the social causes of health, mental health, and the consequences of trauma. He has been listed as one of the most widely cited scholars in the social sciences. He is past chair of the board of the Association of Schools and Programs of Public Health and past president of the Society for Epidemiologic Research and of the Interdisciplinary Association for Population Health Science. He is an elected member of the National Academy of Medicine. Galea has received several lifetime achievement awards. Galea holds a medical degree from the University of Toronto, graduate degrees from Harvard University and Columbia University, and an honorary doctorate from the University of Glasgow.

Holly Garriock, PhD

Chief Cohort Development Officer, All of Us Research Program
National Institutes of Health

Holly A. Garriock, Ph.D., is the Chief Cohort Development Officer for the All of Us Research Program. Holly came to All of Us from the National Institute of Mental Health, where she managed a research portfolio of child and adolescent depression, anxiety, suicide, and trauma that supported her growth and expertise in the fields of child development and mood disorders. Holly did her undergraduate training in Canada; graduate training at the University of Arizona, where she received her Ph.D. in genetics; and postdoctoral research at the University of California, San Francisco.

Magali Haas, MD, PhD

CEO & President
Cohen Veterans Bioscience

Dr. Haas is Chair, CEO and President of Cohen Veterans Bioscience, a non-profit brain research organization based in New York City whose mission is to fast-track diagnostics and therapeutics to advance precision brain health. Magali has over 15 years of pharmaceutical executive experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in early and late stage neuroscience clinical development, translational medicine, diagnostics and integrative solutions. To pioneer new approaches for precision therapeutics for brain health, she founded Orion Bionetworks in 2012, which was transformed to Cohen Veterans Bioscience in 2015, while also serving as founding Chief Science and Technology Officer for One Mind for Research. She serves on several advisory boards including Alto Neurosciences, Partnership for Assessment and Accreditation of Scientific Practice, VirtualBrainCloud, Krembil Centre for Neuroinformatics and IMEC for nanoelectronics. Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, and her MD and PhD in neuroscience with distinction from Albert Einstein College of Medicine.

Anthony M. Hassan, EdD, LCSW

President & CEO
Cohen Veterans Network

Anthony Hassan is the inaugural President and CEO of the Cohen Veterans Network (CVN). Dr. Hassan leads and executes the strategic, operational, and financial direction for the $275M Network which is tasked with carrying out the establishment of 25 mental health clinics nationwide. In addition, he leads CVN’s efforts to advance the field as a learning mental health system through funded research initiatives and training programs that improve care within the Network and set CVN up to serve as a model for others. Hassan is a veteran of the United States Army enlisted and Air Force officer with 30 years of experience in military behavioral health, serving as a military social work officer, leader, clinician, and academic. He served during Operation Iraqi Freedom in 2004 on the first-ever Air Force combat stress control and prevention team embedded with the Army. Hassan’s last military assignment was at the U.S. Air Force Academy where he served as the Deputy Department Head, Leadership Directorate, and led the only graduate-level degree program at the Air Force Academy for top-tier Air Force Commanders. Prior to CVN, Hassan served as the inaugural Director and Clinical Professor of the Center for Innovation and Research on Veterans & Military Families at the University of Southern California School of Social Work. Dr. Hassan’s former military and academic roles have positioned him to develop strong relationships with the most senior levels of leadership in the U.S. Department of Defense, U.S. Department of Veterans Affairs, and Washington, D.C. Hassan holds a Doctorate in Higher Education Administration from the University of South Florida and is an alumnus of the Harvard Business School.

Brad Herbert, MBA

CEO
Healthy Brains Global Initiative

Brad Herbert has more than 40 years of experience in international development with a focus in the social sectors, including health and education. Brad worked with the World Bank for 29 years and spent the majority of his tenure based in developing countries, learning firsthand the value of country-led partnerships.  

In 2002, he left the World Bank to help establish the Global Fund to Fight HIV/AIDs, TB and Malaria. At the Global Fund, Brad was the Chief of Operations, with the rank of Assistant Secretary General at the World Health Organization. While at the Global Fund, he was directly responsible for putting in place the operational policies and the management team responsible for delivering the Global Fund’s multi-billion-dollar grant program in over 130 countries.  Brad has also spent many years serving on and chairing boards for international not-for-profit organizations.  He chaired the board of Mothers 2 Mothers, a not-for-profit organization based in Cape Town and in 2017 was asked by the new Deputy Secretary General of the UN to take over as Co-Chair of the Water Supply and Sanitation Collaborative Council, a UN organization based in Geneva. 

Brad has managed major changes in management processes and helped to restructure several organizations. As a result of these years of development experience, his leadership roles, and his practical results-oriented approach to program policy, development, and accelerated program implementation, Brad was asked to take on the role of the first CEO of the Healthy Brains Global Initiative (HBGI).  

Peter Hoehn

Head, Commercial Strategy
Johnson & Johnson Science for Minds

Peter Hoehn is currently Head, Commercial Strategy for Johnson & Johnson Science for Minds, focusing on innovative digital solutions and data for Serious Mental Illness and dementia.  In this role Peter is responsible for developing the overarching global strategy, portfolio recommendations, investment approach, external collaborations, and business models to establish new value creating digital business ventures.

Previously, Peter Hoehn was the Co Dx, Commercial Strategy Leader within the Global Commercial Strategy Organization of Janssen Pharmaceuticals, responsible for leading strategic marketing and market access for companion and complementary diagnostics (Co Dx) across all Therapeutic Areas.  Peter and his team lead the assessment of potential diagnostic projects and commercial evaluation of prospective diagnostic partners, and lead commercial strategy development, market access strategy and launch readiness for Janssen Co Dx projects.

Peter joined Johnson & Johnson in 2003 in the Pharmaceuticals Group Strategic Marketing organization as Global Commercial Leader for Reminyl, and in 2005 was promoted to Global Marketing Leader – Neurology, where he had global commercial responsibility for in-line neurology products as well as products in late stage of development.  In 2008 Peter joined the Ortho Clinical Diagnostics (OCD) organization as Global Marketing Leader and was promoted to Vice President for WW Marketing and Strategic Marketing in 2010, and continued in this role at OCD until moving back to the Janssen Pharmaceuticals Business as Co Dx Commercial Strategy Leader. 

Peter received a BA in Government and Economics from the College of William and Mary, and a JD from New York University.  He started his career as a corporate lawyer, and entered the pharmaceutical industry as an attorney for Bristol Myers Squibb. After a short time as a lawyer at BMS, Peter moved into various strategy, marketing and sales management roles.

Lee Lancashire, PhD

Chief Information Officer
Cohen Veterans Bioscience

Lee Lancashire, PhD has over 15 years of experience in machine learning and statistics. His PhD was focused on the development of artificial neural network based methodologies where he was involved in many of the first applications of neural nets to high dimensional datasets in bioinformatics.

Prior to joining Cohen Veterans Bioscience, Lee spent over five years within the IP&Science business of Thomson Reuters where he established and led the machine learning and statistical data analysis team. Here he held global responsibility for managing and delivering analytical projects, serving the majority of the top 10 pharmaceutical companies, as well as government, academic and non-profit organizations. These projects focused on utilizing advanced machine learning approaches in the molecular profiling of disease for biomarker discovery, patient stratification and drug target identification.

Lee completed his post-doctoral research in Biostatistics and Bioinformatics at the Paterson Institute for Cancer Research, a Cancer Research UK core facility. He has also worked as a bioinformatics project lead in personalized medicine and diagnostics companies CompanDX and Almac Diagnostics. He has published in over 30 key industry journals and holds several patents around the use of neural networks in the biomedical domain.

In his free time Lee devotes time volunteering as a trustee for the Ichthyosis Support Group, a charity that supports individuals and families affected by a group of rare skin disorders.

Pierre Meulien, PhD

Executive Director
Innovative Medicines Initiative

Pierre Meulien is executive director of the Innovative Medicines Initiative (IMI), a €5 billion public-private partnership between the European Union and the European pharmaceutical industry. At IMI, he is responsible for the overall management of the program, which works to improve and accelerate the drug development process by facilitating collaboration between the key players involved in health research. Previously, Dr Meulien was president and CEO of Genome Canada, where he raised money and oversaw the launch of novel projects and networks in the field of genomics-based technologies. Prior to that, he was chief scientific officer for Genome British Columbia and was the founding CEO of the Dublin Molecular Medicine Center. Dr Meulien also worked with the French biotechnology company Transgene and with Aventis Pasteur (now Sanofi Pasteur). He has a Ph.D. in molecular biology from the University of Edinburgh and carried out a postdoctoral fellowship at the Institut Pasteur in Paris.

Lita Sands, MBA

Head of Global Life Sciences Business Development
Amazon Web Services

Lita joined AWS in 2017 as the Worldwide Head of Biopharma business development for AWS. In this role, she is focused on accelerating the transformation of the value chain through advanced cloud-based capabilities to drive better outcomes for patients, caregivers and healthcare providers. Some of the initiatives she has sponsored include the AWS HCLS Data Exchange, to accelerate research in rare diseases and oncology; the digital connected lab, to enable remote, global research collaborations; and the HCLS alliance with Deloitte’s ConvergeHEALTH to scale real-world evidence.

She has led large-scale transformation initiatives for pharmaceutical companies such as Novartis, Pfizer and Pharmacia. In her most recent client role, she built the US and Global Omni-Channel and Digital capabilities for Novartis, building solutions for customer facing teams around the globe and introducing the first digital patient offering for primary care, with an award-winning COPD application based on the quantified self theory.

Lita is a member of the inaugural MM&M Top 40 Healthcare Transformers, a contributing member of Clinical Trial Transformation Initiative (CTTI) use of mobile devices guidelines and their tech advisory board, and a founding member of Digital Medicine Society DiME. She received a B.S. with a dual major in Computer Science and Marketing from Kean University and an M.B.A. from the Wharton School of Business.

Chris Van Hoof, PhD

Vice President, R&D
imec

General Manager
OnePlanet Research Center in Gelderland

Chris believes preventive health, personalised nutrition, sustainable food production and reduced waste are essential enablers of improving our world for the generations to come. And he is convinced that technology (hardware and AI) are key tools to make that happen.

After receiving a PhD in Electrical Engineering from the University of Leuven in 1992, Chris has held positions as manager and director at imec in highly diverse fields spanning technology, circuits, systems, data and applications. Apart from delivering industry-relevant innovative solutions to customers, his work also resulted in five startups (four in the healthcare domain). He is also full professor at the University of Leuven and imec Fellow.